Equities research analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research report on Friday, November 15th.
Check Out Our Latest Research Report on AEMD
Aethlon Medical Price Performance
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Featured Articles
- Five stocks we like better than Aethlon Medical
- Bank Stocks – Best Bank Stocks to Invest In
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- Canada Bond Market Holiday: How to Invest and Trade
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Industrial Products Stocks Investing
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
